ARK5 inhibitors (Columbia University/Columbia Technology Ventures)

N/A

Report date: 2025/03/18 18:06:49
NME

Base Information

Drug NameARK5 inhibitors (Columbia University/Columbia Technology Ventures)
Drug Alias Nameadrenergic receptor kinase 5 inhibitors (Columbia University/Columbia Technology Ventures)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNUAK family SNF1-like kinase 1 inhibitors
TargetsNUAK family SNF1-like kinase 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesColumbia University
China Registration ClassN/A

Develop Information

Active CompaniesColumbia Technology VenturesColumbia University
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A